Nothing said here yet.
to join the conversation.
| WILSON JAMES NDirector | Sell | 6,654 | $761.7K | Thu, Oct 15 |
| WILSON JAMES NDirector | Sell | 3,046 | $351.5K | Thu, Oct 15 |
| WILSON JAMES NDirector | Sell | 300 | $34.9K | Thu, Oct 15 |
| Maduck SeanSee Remarks | Sell | 15,843 | $1.8M | Fri, Oct 2 |
| Maduck SeanSee Remarks | Sell | 8,744 | $1.0M | Fri, Oct 2 |
| Vieira Roberto WandenkolkPresident, Oncology | Sell | 5,147 | $600.1K | Fri, Oct 2 |
| Lyon Joseph DouglasSee Remarks | Sell | 4,744 | $552.9K | Fri, Oct 2 |
| Lyon Joseph DouglasSee Remarks | Sell | 4,446 | $514.4K | Fri, Oct 2 |
| Vieira Roberto WandenkolkPresident, Oncology | Sell | 2,086 | $241.4K | Fri, Oct 2 |
| Vieira Roberto WandenkolkPresident, Oncology | Sell | 1,100 | $126.0K | Fri, Oct 2 |
| Lyon Joseph DouglasSee Remarks | Sell | 810 | $93.5K | Thu, Oct 1 |
| Maduck SeanSee Remarks | Sell | 413 | $47.7K | Thu, Oct 1 |
Corcept Therapeutics recently reported Part A results from its Phase 2 BELLA trial.
For questions about this article or underlying research, email [email protected].
CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
Corcept Therapeutics has delivered very strong long term returns, which naturally raises a harder question for you as an investor.
Corcept Therapeutics (CORT) is back in focus after options traders clustered around the November 20, 2026 $47.50 put, which recently showed some of the highest implied volatility among individual equity contracts.
Investors need to pay close attention to CORT stock based on the movements in the options market lately.
Corcept Therapeutics, Stock Of The Day fell amid a medical sell-off, but has pared losses to near buy points. Earnings growth is booming.